Regulatory ReimbursementThe NOPAIN reimbursement change offers additional incentives, potentially boosting Exparel's pricing strategy positively.
Settlement AgreementThe settlement agreement with Fresenius provides Exparel exclusivity into 2039, enhancing the stock's potential for growth.
Share Repurchase ProgramA new $300MM share repurchase program has been announced, signaling confidence in the company's financial health.